.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,648,214

« Back to Dashboard

Details for Patent: 5,648,214

Title: High-affinity oligonucleotide ligands to the tachykinin substance P
Abstract:Methods are described for the identification and preparation of nucleic acid ligands to Substance P (SP). Included in the invention are specific RNA ligands to SP identified by the SELEX method.
Inventor(s): Nieuwlandt; Dan T. (Boulder, CO), Gold; Larry (Boulder, CO), Wecker; Matthew (Boulder, CO)
Assignee: University Research Corporation (Boulder, CO)
Filing Date:Sep 09, 1994
Application Number:08/303,362
Claims:1. A method of identifying nucleic acid ligands to Substance P (SP), comprising:

a) preparing a candidate mixture of nucleic acids;

b) contacting said candidate mixture of nucleic acids with SP, wherein nucleic acids having an increased affinity to SP relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with said increased affinity to SP, whereby nucleic acid ligands of SP may be identified.

2. The method of claim 1 further comprising:

e) repeating steps b), c) and d).

3. The method of claim 1 further comprising:

e) contacting, between steps (c) and (d), the increased affinity nucleic acids with one or more non-substance P molecules, wherein nucleic acids with an affinity to the non-Substance P molecules(s) is are removed.

4. The method of claim 1 further comprising:

e) preparing a second candidate mixture of nucleic acids by mutagenizing the mixture of increased affinity nucleic acids; and

f) repeating steps (b), (c) and (d), whereby nucleic acid ligands of SP may be identified.

5. The method of claim 1 wherein said candidate mixture of nucleic acids is comprised of single-stranded nucleic acids.

6. The method of claim 5 wherein said single-stranded nucleic acids are ribonucleic acids.

7. The method of claim 5 wherein said single-stranded nucleic acids are deoxyribonucleic acids.

8. A method for identifying nucleic acid ligands from a candidate mixture of nucleic acids, said nucleic acid ligands being a ligand of a given target molecule comprising:

a) contacting said candidate mixture with the target molecule, wherein nucleic acids having increased affinity to the target molecule may be partitioned from the remainder of the candidate mixture;

b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;

c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids;

d) preparing a second candidate mixture of nucleic acids by mutagenizing the ligand-enriched mixture of nucleic acids, whereby nucleic acid ligands of the given target molecule may be identified.

9. The method of claim 8 further comprising:

e) repeating steps (a), (b), and (c).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc